Adults on pre-exposure prophylaxis (tenofovir-emtricitabine) have faster clearance of anti-HIV monoclonal antibody VRC01

Broadly neutralizing monoclonal antibodies (mAbs) are being developed for HIV-1 prevention. Hence, these mAbs and licensed oral pre-exposure prophylaxis (PrEP) (tenofovir-emtricitabine) can be concomitantly administered in clinical trials. In 48 US participants (men and transgender persons who have...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Yunda, Zhang, Lily, Karuna, Shelly, Andrew, Philip, Juraska, Michal, Weiner, Joshua A., Angier, Heather, Morgan, Evgenii, Azzam, Yasmin, Swann, Edith, Edupuganti, Srilatha, Mgodi, Nyaradzo M., Ackerman, Margaret E., Donnell, Deborah, Gama, Lucio, Anderson, Peter L., Koup, Richard A., Hural, John, Cohen, Myron S., Corey, Lawrence, McElrath, M. Juliana, Gilbert, Peter B., Lemos, Maria P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10684488/
https://www.ncbi.nlm.nih.gov/pubmed/38016958
http://dx.doi.org/10.1038/s41467-023-43399-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10684488/
https://www.ncbi.nlm.nih.gov/pubmed/38016958
http://dx.doi.org/10.1038/s41467-023-43399-5

Ejemplares similares